vedolizumab + ustekinumab + tofacitinib

This is an experimental combination therapy consisting of three agents with distinct mechanisms of action, used off-label in the management of refractory inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. - **Vedolizumab** is a monoclonal antibody that targets the α4β7 integrin, inhibiting lymphocyte trafficking to the gut and thereby reducing gut inflammation. - **Ustekinumab** is a monoclonal antibody that inhibits interleukin-12 (IL-12) and interleukin-23 (IL-23), key cytokines involved in inflammatory pathways. - **Tofacitinib** is an oral small molecule inhibitor of Janus kinases (JAKs), primarily JAK1 and JAK3, interfering with intracellular signaling for multiple pro-inflammatory cytokines. The rationale for combining these drugs lies in their complementary mechanisms targeting different aspects of immune dysregulation in IBD. This triple therapy has been explored mainly in patients who have failed multiple prior therapies or have particularly severe or complicated disease phenotypes[1][3][9]. Published case series and retrospective studies suggest potential clinical benefit without new safety signals, but this regimen remains investigational and should only be considered under expert supervision at specialized centers[1][3].